01—Abstract
Summary
Summary of the 8-K filed February 21, 2024. Cited figures are marked; the original filing is the authoritative source.
On February 20, 2024, Ventas, Inc. (VTR) filed a Registration Statement on Form S-3 (File No. 333-277185) that replaces its existing Form S-3 (File No. 333-253415), which expires on February 23, 2024.
The registration statement became effective automatically upon filing. In connection with it, the company filed a new prospectus supplement for its existing “at the market” equity offering program, reflecting an amendment to the Sales Agreement. On the same date, Ventas entered into Amendment No. 1 to the ATM Sales Agreement dated November 8, 2021.
The amendment references the Replacement Registration Statement, adds and removes certain sales agents and forward purchasers, and increases the aggregate gross sales price of common stock available under the agreement to $1,000,000,000a. The filing states that an aggregate gross price of $110,400,000 of common stock has been offered and sold under the Sales Agreement through February 20, 2024. Following the amendment, the company may offer and sell up to $1,000,000,000 of common stock from time to time through the agents.
For investors, the filing signals potential future equity issuance capacity of up to $1.0 billionb, which could dilute existing shareholders depending on how much is sold. The filing also includes Davis Polk & Wardwell LLP's opinion on the validity of shares that may be issued (Exhibit 5.1). The filing includes standard forward-looking statement cautions, including a reference to the risk of potential dilution from future equity sales.
02—Key points
Key Highlights
- Filed a replacement Form S-3 (File No. 333-277185) on February 20, 2024, effective automatically upon filing, replacing the registration statement that expires on February 23, 2024.
- Amended the ATM Sales Agreement dated November 8, 2021 (Amendment No. 1), dated February 20, 2024.
- Increased the aggregate gross sales price of common stock available under the at-the-market program to $1,000,000,000.
- Approximately $110,400,000 aggregate gross price of common stock had been offered and sold under the Sales Agreement through February 20, 2024.
- Added and removed certain sales agents and forward purchasers, including Bank of America, BNP Paribas, Citigroup, Jefferies, JPMorgan, Morgan Stanley, Wells Fargo and others.
- Filed a new prospectus supplement reflecting the amended Sales Agreement on February 20, 2024.
- Exhibits include Amendment No. 1 (Exhibit 1.1) and Davis Polk & Wardwell LLP's opinion on share validity (Exhibit 5.1).
03—Questions
Frequently Asked Questions
What is the purpose of this 8-K filing?
The filing reports a replacement Form S-3 shelf registration, a new prospectus supplement for the at-the-market equity program, and Amendment No. 1 to the Sales Agreement, which increases the program size to $1.0 billion.
How much common stock can Ventas now sell under its at-the-market program?
Under Amendment No. 1, Ventas may offer and sell shares of common stock with an aggregate gross sales price of up to $1,000,000,000 through the agents.
How much has already been sold under the Sales Agreement?
The filing states that an aggregate gross price of $110,400,000 of common stock had been offered and sold under the Sales Agreement through February 20, 2024.
Why did Ventas file a new registration statement?
The company's existing Form S-3 (File No. 333-253415) expires on February 23, 2024, so it filed a replacement Form S-3 (File No. 333-277185) on February 20, 2024, which became effective automatically upon filing.
What risks does the filing highlight for investors?
The forward-looking statements section lists risks including the potential for dilution resulting from future sales or issuances of equity securities, along with the factors described in the company's periodic SEC filings.
04—Continue